Chronic inflammation, fibrosis, atrophy, malignant transformation and thromboembolic events are hallmarks of chronic pancreatic disease. Extracellular nucleotides have been implicated as inflammatory mediators in many pathological situations. However, there are minimal data detailing expression of ectonucleotidases and type-2 purinergic receptors (P2-R) in chronic pancreatitis and pancreatic cancer. We have therefore defined tissue distribution and localization of the CD39 family of ectonucleotidases and associated P2-R in human disease. Transcripts of ectonucleotidases (CD39, CD39L1) together with P2-R (P2X7, P2Y2 and P2Y6) are significantly increased in both chronic pancreatitis and pancreatic cancer. CD39 and CD39L1 are preferentially associated with the vasculature and stromal elements in pathological tissues. P2X7 mRNA upregulation was associated with chronic pancreatitis and heightened protein expression was found to be localized to infiltrating cells. P2Y2 was markedly upregulated in biopsies of pancreatic cancer tissues and expressed by fibroblasts adjacent to tumors. High tissue mRNA levels of CD39 significantly correlated with better long-term survival after tumor resection in patients with pancreatic cancer. Heightened expression patterns and localization patterns of CD39, P2X7 and P2Y2 infer associations with chronic inflammation and neoplasia of the pancreas. Our data suggest distinct roles for CD39 and P2-purinergic signaling in both tissue remodeling and fibrogenesis with respect to human pancreatic diseases.
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Introduction:
Clinically important pancreatic diseases may be classified as acute pancreatitis (AP), chronic pancreatitis (CP) and pancreatic cancer (PaCa) To control for specificity of the amplification products, a melting curve analysis was performed. No amplification of unspecific products was observed. The copy number was calculated from a standard curve, obtained by plotting known input concentrations of four different plasmids at log dilutions to the PCR-cycle number (CP) at which the detected fluorescence intensity reaches a fixed value. This approach dramatically decreased variations due to handling errors over several logarithmic dilution steps.
To correct for differences in the content of total RNA, calculated copy numbers were normalized according to the average expression of two housekeeping genes, Cyclophilin B and HPRT. Values were thus given as input adjusted copy number per Nl of cDNA.
Cell lysate preparation and Western Blot
Cell lysates were prepared using a homogenate buffer (containing 20 mM Tris, 100 mM NaCl, 0.1 mM PMSF, 10 µg/ml aprotinin, 1% NP-40). After sonication and centrifugation Mayer's hematoxylin, dehydrated, cleared in xylene, and mounted in Permount. All antibodies were diluted in solution 9, unless otherwise indicated. Optimal antibody concentrations were determined by serial dilution.
Statistical Analysis
Results are expressed as median and range and/or mean ± SD. For statistical analysis the Mann-Whitney test was used. Survival curves were computed by the Kaplan-Meier method as analyzed by the log-rank test. Significance was defined as p<0.05. For survival analysis the samples were segregated according to the fold increase in mRNA expression levels compared with normal controls in positive and negative tumors. The cut-off levels (number of mRNA copies) were set for CD39 at 410 and P2Y2 at 33.
Results:
Altered mRNA levels of NTPDases and P2-R
RT-PCR was performed to determine mean levels of mRNA expression of CD39, CD39L1, P2X7, P2Y1, P2Y2 and P2Y6. CD39, CD39L1, P2X7 and P2Y1 were expressed at low levels in NP. P2Y2 and P2Y6 mRNA levels in NP were near zero. In CP, expression levels of mRNA for CD39 (5.0-fold increment, p=0.0006) and P2X7 (3.0-fold increment, p=0.0024) were significantly and substantially increased. In contrast, CD39L1 (1.3-fold increase, p=0.0122), P2Y2 (2.1-fold increase, p=0.0098) and P2Y6 (2.3-fold increase, p=0.0185) were only moderately overexpressed in CP, as compared to NP (Fig. 1) .
Both of the NTPDases tested were highly overexpressed in PaCa (CD39: 13.3-fold increase, p=0.0007; CD39L1: 3.7-fold increase, p=0.0126). P2Y-R mRNA levels increased in PaCa as compared to normal pancreas (P2Y2: 11.7-fold increase, p=0.0008; P2Y6: 4.4-fold increase, p=0.0011), whereas P2Y1 and P2X7 were unchanged (P2Y1: 0.8-fold increase, n.s.) and P2X7 only moderately but not significantly overexpressed (1.8-fold increase, n.s.) (Fig. 1) . Interestingly, both NTPDases (CD39 and CD39L1) as well as P2Y2 and P2Y6 were significantly overexpressed in CP as well as PaCa, whereas P2X7 was not upregulated in PaCa. P2X7 transcripts were significantly upregulated in CP when compared to PaCa (p=0.0247), whereas those of P2Y2 were significantly overexpressed in PaCa, as compared to CP (p=0.0209).
Overexpression of CD39 and purinergic receptors
Low levels of CD39, CD39L1, P2X7, P2Y2 and P2Y6 expression were noted in normal representative pancreatic biopsies, (Fig. 2A ). CD39 and especially P2X7 were upregulated and highly expressed in CP. CD39L1 and P2Y2 were moderately expressed in CP where levels were comparable with findings in normal pancreas. PaCa samples exhibited heightened levels of CD39 and P2Y2, validating mRNA findings of overexpression. High levels of both intact CD39 (78kDa) and truncated proteolytic fragments (50kDa) were observed. P2X7, expressed as a double band at about 79kDa, was overexpressed in CP. In contrast to elevated P2X7 in CP, P2Y2 (~47kDa) was only specifically overexpressed in PaCa ( Fig. 2A) . Measurements of protein expression in relation to GAPDH expression revealed a trend towards increased expression by 2.75-fold (p=n.s.) in the instance of CD39 levels in CP. In PaCa, CD39 expression was however, significantly increased by 2.75-fold (p=0.0070) (Fig. 2B) . Expression levels of P2X7 show a 3-fold increase in CP and a 2.2-fold increase of protein expression in PaCa, when compared to P2X7 protein expression (in NP). Although at the mRNA level, P2X7 was overexpressed in CP when compared to NP, at the protein level, differences in P2X7 expression between CP and NP, did not achieve statistical significance (p=0.11). P2Y2 protein expression level appeared comparable in both NP and CP (1.7
time increase, p=n.s.) but there was a 3.1-fold increase in PaCa, as compared to NP, (p=0.0281). (Fig. 3A, 3D , 3G, 3K).
Specific localization of CD39 and P2-R
In CP, NTPDases were greatly overexpressed. CD39 was localized to stromal tissue and vasculature of CP. CD39L1 was moderately expressed in fibroblast like structures.
P2X7 in CP was localized to immune cells. P2Y2 expression levels were high in fibroblastic areas but not in pancreatic parenchyma (Fig. 3B, 3E 3H, 3L ).
In PaCa, CD39 was highly expressed around malignant cells in stromal elements.
However, cancer cells as well as normal acinar cells do not express CD39 to any extent.
CD39L1 localization to nerves can be clearly shown in Figure 3F (Fig. 3C, 3F , 3I, 3M).
High CD39 expression in PaCa correlates with better clinical outcomes
To evaluate the clinical significance of mRNA expression in pancreatic cancer samples,
RT-PCR results were correlated with survival data and histopathological parameters after tumor resection (Table. 2). Patients where tumors exhibited overall elevated high levels of CD39 mRNA, had significantly longer median postoperative survival periods (CD39: median 33 months; mean ± SD 29.7 ± 20.94 months) than patients whose tumors exhibited low to moderate CD39 mRNA levels (CD39: median 14 months; mean ± SD 20.1 ± 16.56 months). These differences were statistically significant when analyzed by the log-rank test (CD39: p=0.0466) (Fig. 4 ). There were no significant relationships noted for CD39L1, P2Y2 and P2Y6 mRNA expression, postoperative patient survival and tumor stage (Table. 2)
Clinicopathological features in patients with CP (Table. 1 Overexpression of CD39 and correlation to longterm survival after tumor resection for pancreatic cancer also suggest potential, highly novel role for purinergic signaling in PaCa.
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